Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors

Table 1

Clinical features of multifocal or solitary papillary thyroid cancer.

Clinical characteristics	All patients	Multifocal	Solitary	value
Patient number	2536 (100.0)	626 (24.7)	1910 (75.3)
Gender, female	1996 (78.7)	499 (79.7)	1497 (78.4)	0.479
Age at diagnosis (year)	43.7 ± 14.0	46.5 ± 13.5	42.7 ± 14.0	<0.001
	1174 (46.3)	355 (56.7)	819 (42.9)	<0.001
Mean tumor size (cm)	2.3 ± 1.6	2.1 ± 1.4	2.3 ± 1.6	0.003
1-month postoperative serum Tg level (ng/mL)	157.4 ± 1851.2	184.2 ± 1551.1	148.6 ± 1939.7	0.683
Variants
Hashimoto (lymphocytic) thyroiditis	133 (5.2)	29 (4.6)	104 (5.4)	0.429
Follicular variant of PTC	382 (15.1)	99 (15.8)	293 (15.3)	0.776
Poorly differentiated + tall cell	36 (1.4)	8 (1.3)	28 (1.5)	0.730
Operative method
Total thyroidectomy	2191 (86.4)	595 (95.0)	1596 (83.6)	<0.001
TNM stage
Stage I	1772 (69.9)	390 (62.3)	1382 (72.4)	<0.001
Stages II–IV	764 (30.1)	236 (37.7)	528 (27.6)
Nonremission	381 (15.0)	131 (20.9)	250 (13.1)	<0.001
Follow-up period (year)	9.4 ± 6.8	7.1 ± 5.3	10.2 ± 7.0	<0.001
Postoperative ^131I accumulative dose (mCi)	130.6 ± 199.9	153.7 ± 222.2	123.0 ± 191.4	0.001
Radiation therapy	114 (4.5)	28 (4.5)	86 (4.5)	0.975
2nd primary cancer	180 (7.1)	49 (7.8)	131 (6.9)	0.413
Diabetes mellitus	210 (8.3)	61 (9.7)	149 (7.8)	0.126
Overall mortality	227 (9.0)	49 (7.8)	178 (9.3)	0.256
Cancer mortality	109 (4.3)	25 (4.0)	84 (4.4)	0.665
Disease-free	982 (38.7)	221 (35.3)	761 (39.8)	0.043
Lymph node metastasis	581 (22.9)	197 (31.5)	384 (20.1)	<0.001
Soft tissue invasion	520 (20.5)	153 (24.4)	367 (19.2)	0.005
Distant metastasis	112 (4.4)	39 (6.2)	73 (3.8)	0.011

Number (%); mean ± SD.